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The oncogene Gankyrin is expressed in
testicular cancer and contributes to
cisplatin sensitivity in embryonal carcinoma
cells
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Abstract
Background: Testicular germ cell cancer (TGCC) develops from pre-malignant germ neoplasia in situ (GCNIS) cells.
GCNIS originates from fetal gonocytes (POU5F1+/MAGE-A4−), which fail to differentiate to pre-spermatogonia
(POU5F1−/MAGE-A4+) and undergo malignant transformation. Gankyrin is an oncogene which has been shown to
prevent POU5F1 degradation and specifically interact with MAGE-A4 in hepatocellular carcinoma (HCC) cells. We
aimed to investigate the role of Gankyrin in progression from gonocyte to pre-invasive GCNIS and subsequent
invasive TGCC.
Methods: We determined Gankyrin expression in human fetal testicular tissue (gestational weeks 9–20; n = 38), human
adult testicular tissue with active spermatogenesis (n = 9), human testicular tissue with germ cell maturation delay (n =
4), testicular tissue from patients with pre-invasive GCNIS (n = 6), and invasive TGCC including seminoma (n = 6) and
teratoma (n = 7). Functional analysis was performed in-vitro by siRNA knock-down of Gankyrin in the NTera2 cells
(derived from embryonal carcinoma).
Results: Germ cell expression of Gankyrin was restricted to a sub-population of prespermatogonia in human fetal
testes. Nuclear Gankyrin was also expressed in GCNIS cells of childhood and adult pre-invasive TGCC patients, and
in GCNIS from seminoma and non-seminoma patients. Cytoplasmic expression was observed in seminoma
tumour cells and NTera2 cells. Gankyrin knock-down in NTera2 cells resulted in an increase in apoptosis mediated
via the TP53 pathway, whilst POU5F1 expression was unaffected. Furthermore, Gankyrin knock-down in NTera2
cells increased cisplatin sensitivity with an increase in cell death (13%, p < 0.05) following Gankyrin knock-down,
when compared to cisplatin treatment alone, likely via BAX and FAS. Our results demonstrate that Gankyrin
expression changes in germ cells during normal transition from gonocyte to prespermatogonia. In addition,
changes in Gankyrin localisation are associated with progression of pre-invasive GCNIS to invasive TGCC.
Furthermore, we found that Gankyrin is involved in the regulation of NTera2 cell survival and that a reduction in
Gankyrin expression can modulate cisplatin sensitivity.
Conclusions: These results suggest that manipulation of Gankyrin expression may reduce the cisplatin dose required
for the treatment of TGCC, with benefits in reducing dose-dependent side effects of chemotherapy. Further studies are
required in order to assess the effects of modulating Gankyrin on GCNIS/TGCC using in vivo models.
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Background
The incidence of testicular germ cell cancer (TGCC) has
increased over recent decades and is currently the most
common malignancy among young caucasian men [1–3].
The precursor lesion for TGCC, known as Germ Cell
Neoplasia in situ (GCNIS, previously carcinoma in situ)
originates during fetal life when a sub-population of gono-
cytes fail to differentiate normally to (pre) spermatogonia
[4, 5]. Several studies have shown that GCNIS cells resem-
ble gonocytes with regard to morphology, epigenetic pro-
file and protein expression [6–8]. GCNIS cells remain
dormant in the testis until after puberty, when they gain
invasive capacity and develop into invasive tumours [9,
10], histologically classified as seminoma and non-
seminoma [11]. Although models for the pathogenesis of
TGCC have been hypothesized [12], the mechanisms that
result in failure of gonocyte differentiation, development
of GCNIS, and stimulation of proliferation of GCNIS to
gain invasive capacity to form TGCC are incompletely
understood, although an interaction within (epi) genetics
and environmental parameters are assumed [13].
All gonocytes and GCNIS cells express the pluripo-
tency factor POU5F1 (OCT4), whilst a sub-population
of GCNIS cells also express the (pre) spermatogonial
protein MAGE-A4. We have previously shown that
MAGE-A4− GCNIS cells proliferate more frequently
than the MAGE-A4+ population, suggesting that
MAGE-A4 might have an anti-proliferative effect when
expressed in GCNIS cells [14].
Gankyrin is an oncogene that has previously been
shown to be involved in the pathogenesis of several can-
cers including colorectal cancer [15, 16], breast cancer
[17–19] and hepatocelullar carcinoma [20–25]. MAGE-
A4 has been shown to suppress the oncogenic properties
of Gankyrin leading to reduced tumour size in a mouse
model of Gankyrin overexpression [26]. Gankyrin also
prevents POU5F1 degradation in hepatocellular carcin-
oma (HCC) by inhibiting the interaction of POU5F1
with WW domain containing E3 ubiquitin protein ligase
(WWP2 [23, 27];. POU5F1 has also been shown to be
negatively regulated by WWP2 in NTera2 (embryonal
carcinoma) cells [27].
Cisplatin based chemotherapy is frequently used for
treatment of TGCC, resulting in a high cure rate [28,
29]. However, cisplatin treatment also results in signifi-
cant adverse effects in patients which includes infertility.
It has been hypothesized that the efficiency of cisplatin
based chemotherapy in TGCC is due at least in part to
the high expression of wildtype TP53 in TGCC [30, 31].
It has been previously shown that TP53 is required by
cisplatin to facilitate cytotoxicity [32] and that the pre-
dominant mechanism of cisplatin cytotoxicity in TGCC
is due toTP53 hypersensitivity [33]. This has been dem-
onstrated in the TGCC cell line NTera2 and 2102EP
[34]. Gankyrin has been linked to TP53 in HCC [22, 35],
where it has been shown that Gankyrin mediates the
degradation of tumour suppressor proteins such as TP53
[36, 37]. However, there have been no previous studies
examining the effect of Gankyrin manipulation on TP53
and downstream signalling in TGCC.
We hypothesized that Gankyrin expression in the
human fetal testis is associated with germ cell maturation
and malignant transformation. We also hypothesized
that Gankyrin regulates the oncogenic potential and
cisplatin sensitivity of NTera2 cells via the TP53
pathway.
Methods
The study aim was to characterize Gankyrin expression
in human testicular tissues from fetal life through adult-
hood and to compare with GCNIS and TGCC. Further-
more, we aimed to investigate the impact of Gankyrin
knockdown on cell death and cisplatin sensitivity in em-
bryonal carcinoma cells.
Tissue collection
Human fetal testis tissue
Human fetal testicular tissue was obtained following
elective termination of pregnancy during gestational
weeks 9 to 20 (n = 38). Women gave informed consent
and tissue was collected with ethical approval (REC ref-
erence: LREC08/1101/1 and 08/H0906/21 + 5). Gesta-
tional age was determined by ultrasound and confirmed
by measuring foot length. Testis tissue was fixed in for-
malin for 24 h, transferred into 70% ethanol and then
embedded in paraffin. Sections of 5 μm thickness were
prepared. Sex was determined by expression of sex de-
termining region gene Y (SRY) gene by qPCR as previ-
ously described [38].
Adult testicular tissue
Testicular tissue with complete spermatogenesis (n = 9)
was obtained from archived material. Orchiectomy was
performed for clinical indications primarily involving
chronic testicular pain. Tissues were fixed in buffered
formalin for pathological assessment. Ethical approval
was obtained for the use of archived human testicular
tissue from the pathology department at the Western
General Hospital in Edinburgh (REC Reference: 10/
S1402/33) and from the biobank at the Department of
Growth and Reproduction, University Hospital of
Copenhagen, Denmark (H-1-2012-007).
Childhood testicular samples with maturation delay
Tissue from children aged 0–2 years with maturation
delay (n = 4) were obtained from Erasmus MC-
University Medical Center, Rotterdam (Institutional re-
view board – MEC 02.981 and CCR2041). Tissues were
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obtained in the context of routine clinical diagnosis of
suspected gonadal anomalies to be evaluated by histo-
logical examination. The samples were handled accord-
ing to existing standard operational protocols and
evaluated by an experienced clinical uro-pathologist. Left
over tissue was approved to be used for scientific re-
search. The diagnosis of maturation delay is reached
when in children above 6 months, POU5F1+ germ cells
with round nuclei present in the lumen of a seminifer-
ous tubule can be observed [39].
TGCC samples
Tissue from children (n = 2) and adults (n = 4) with pre-
invasive disease (pre-GCNIS cells or GCNIS cells with-
out evidence of invasive tumour) were obtained from
Erasmus MC-University Medical Center, Rotterdam (In-
stitutional review board – MEC 02.981 and CCR2041)
and from the biobank at the Department of Growth and
Reproduction, University Hospital of Copenhagen,
Copenhagen, Denmark (H-1-2012-007). Samples from
pre-GCNIS patients were diagnosed by the presence of
OCT4+ cells which can co-express TSPY in a heteroge-
neous pattern accompanied by focal KITLG expression.
These cells been relocated from the center of the tubule
to the pre-spermatogonial niche at the basement mem-
brane [39]. These tissues were obtained from patients
with Disorders of Sexual Development (DSD), infertility,
or suspected TGCC for diagnostic purposes. Invasive
TGCC tissue was obtained from clinical orchiectomy
specimens from men with seminoma, (n = 6) and tera-
toma (n = 7). These tissues contained regions with histo-
logically normal spermatogenesis, GCNIS cells or the
tumour component. Tissues were randomly selected and
the presence of GCNIS cells was confirmed by light mi-
croscopy prior to commencing the study.
Triple immunofluorescence
Sections were dewaxed in xylene, rehydrated in graded
alcohols and washed in tap water. Antigen retrieval was
performed in 0.01M citrate buffer in a decloaking cham-
ber (Biocare Medical, Berkshire, UK), sections were then
washed in tap water and endogenous peroxidase was
blocked with 3% H2O2 in MeOH for 30 min, followed by
two washes in Tris Buffer saline (TBS) for 5 min. Sec-
tions were blocked with Normal chicken serum (NChS)
for 30 min at room temperature (RT) followed by incu-
bation with POU5F1 antibody (Santa Cruz, Heidelberg,
Germany – sc8628) overnight at 4 °C. The following day
sections were washed twice with TBS for 5 min each and
incubated with chicken anti goat peroxidase labelled
antibody (1 in 200 in NChS) for 30 min, followed by two
5min washes with TBS and incubation with Tyramide
signal amplification (TSA, Perkin Elmer, Waltham,
USA), at 1:50 for 10 min. Sections were microwaved for
2.5 min in 0.01M citrate buffer, followed by a 30 min
cool down period. The process from NChS block up to
primary antibody detection was repeated twice more for
two subsequent primary antibodies MAGE-A4 (gift,
described in [40, 41]) and Gankyrin (Novus Bio –
NBP1–82443). Sections were counterstained with DAPI
(4′, 6-diamidino-2-phenylindole, Sigma, Poole, UK) by
adding 1 μl/mL of TBS and incubating the sections for
10 min in the dark. Finally, sections were washed twice
with TBS for 5 min and mounted with PermaFluor (Life
Technologies, Paisley, UK). Negative controls were no
primary antibody controls and are shown as insets. De-
tails of antibodies used for immunofluorescence can be
found in Table 1.
Western blot
NTera2 cells were resuspended in 50 μl of radioimmu-
noprecipitation assay (RIPA) buffer with protease inhibi-
tors (Roche, Baser, Switzerland). Bradford assay was
used to quantify the amount of protein in each sample
and Western blot was performed with 20 μg of protein
in each lane. Protein was loaded into wells of a NOVEX
SDS/PAGE (Life Technologies) gel, which was run at
150 mA with running buffer (Thermofisher scientific).
Protein was transferred to an Amersham Hybond ECL
nitrocellulose membrane (GE Healthcare Lifesciences,
Buckinghamshire, UK) at 400 V, 250 mA and 50W for
90min. Membranes were then blocked with 5%
skimmed milk powder in PBST (PBS + Tween®20) for 30
min at RT, followed by incubation overnight with the
relevant primary antibody diluted in 5% skimmed milk
in PBST at 4 °C. The following day membranes were in-
cubated for 30 min at RT with a secondary antibody
conjugated with IRDye 680 or 800 (LI-COR Biosciences,
Nebraska, USA) at a concentration of 1 in 10,000, and
scanned in the LI-COR Odyssey scanner (LI-COR Bio-
sciences). Images were captured by Image Studio™ (Li-
COR Biosciences) software. Tubulin or Glyceraldehyde
3-phosphate dehydrogenase (GAPDH) detection were
used as loading controls. Relative protein expression was
quantified with Image Studio™.. Primary antibody details
can be found on Table 1.
Table 1 Details of primary antibodies
Antibody Laboratory Immunofluorescence Western blot
Gankyrin Novus 1 in 10,000 1 in 1000
GAPDH Abcam N/A 1:5000
MAGE-A4 gift 1:300 N/A
POU5F1 Santa Cruz 1:150 1:300
SOX9 Merck Millipore 1:5000 N/A
TP53 Santa Cruz 1:1000 1:1000
Tubulin Abcam N/A 1:5000
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Quantification of nuclear Gankyrin expression
POU5F1 was used to detect GCNIS cells in triple immu-
nostained sections from pre-invasive and invasive TGCC
patients. For each section,10 random fields with GCNIS
were quantified using a LSM710 Zeiss confocal micro-
scope (Carl Zeiss). For sections containing smaller areas
of GCNIS, all GCNIS cells were counted. These images
were then compiled using Image J software (Image J, U.
S. National Institutes of Health, Bethesda, Maryland,
USA). POU5F1+/MAGE-A4− and POU5F1+/MAGE-A4−
GCNIS cells were counted using the cell counter plug-in
in the Image J software. Data was analysed with Graph-
Pad Prism 6.04 (GraphPad software INC., La Jolla, USA).
Gankyrin SiRNA transfection of NTera2 cells
NTera2 cells were cultured with DMEM +1x glutamine
+1x penicillin/streptomycin +10x FCS (all reagents
from ThermoFisher Scientific) at 37 °C and 5%CO2.
Cells were seeded in 12 well plates with 10 × 104 cells
per well on the day prior to transfection. Cells were
transfected with 20 nM of Gankyrin siRNA using
HiPerFect (Qiagen, Redwood City, C. A, U.S.A) trans-
fection reagent diluted in DMEM + glutamine. Gan-
kyrin siRNA (Life Technologies, Paisley, UK) with the
sequence 5′-UUU CGA AGC UGC AUA AUG UAA
GGG A-3′ was used for transfection of NTera2 cells.
Controls included a media only and siRNA control.
After randomization of the plate, cells were incubated
at 37 °C and 5% CO2 for 10 h with Gankyrin siRNA or
siRNA control. After 10 h the media was discarded and
replaced by pre-warmed complete medium (DMEM +
5%FCS + 1x penicillin/streptomycin +1x glutamine).
Cells were then harvested 24 or 48 h after transfection
had commenced. RNA or protein was extracted and
stored at − 80 °C until further analysis. Cells were
counted using the NucleoCounter NC-100 automated
cell count system (Chemometec, Allerod, Denmark).
For in vitro experiments, a minimum of three replicates
per experiment were included. These three replicates
were considered as the experimental unit (n). Experi-
ments were repeated a minimum of three times (n = 3).
Modulation of Cisplatin effects in NTera2 cells
Cisplatin kill curve in NTera2 cells
In order to determine the optimal cisplatin concentra-
tion for moderate (~ 50%) cell death, 12 well plates were
seeded with 10 × 104 NTera2 cells. The following day
(D1), plates were randomized for treatment with 0.25,
0.5, 1, 2, 4, 8, 16 or 100 μM cisplatin for 24 h. On D2,
media was discarded, cells were washed with 1 ml DPBS
(GIBCO, Hemel Hempstead, UK), and cells were dissoci-
ated with 250 μl TrypLE™ Express (Life technologies) for
5 min at 37 °C. Pre-warmed complete medium (750 μl)
was added and the suspension was collected. Cells were
centrifuged for 5 min at 4000 rpm. Media was discarded,
and cells resuspended in 1 ml media. From this suspen-
sion 100 μL was taken for cells counts in the Nucleo-
Counter NC-100 Automated cell count system
(Chemometec). The dose to be used in further experi-
ments was 4 μM of cisplatin for 24 h which corre-
sponded to ~ 50% cell death.
Gankyrin siRNA in cisplatin treated NTera2 cells
To investigate the effects of Gankyrin knock-down on
cisplatin sensitivity on NTera2 cells, cisplatin treatments
(24 h) was initiated following transfection with siRNA
targeting Gankyrin expression for 24 h. Cells were then
harvested and quantified in the NucleoCounter NC-100
automated cell count system (Chemometec).
Cell cycle analysis
Cell cycle analysis was performed in a 5 laser LSR For-
tessa (BD Bioscience) flow cytometer. DNA was stained
with HOECHST (Cell Signalling) and viability assess-
ment was performed with propidium iodide staining.
After harvesting cells as described above for the modula-
tion of cisplatin effects in NTera2 cells section, cells
were resuspended in a 15 μg/μl HOECHST (diluted in
2%FCS DPBS) solution and incubated in the dark for 30
min at 37 °C prior to cell cycle analysis.
Apoptosis assay
NTera2 cells were cultured with DMEM +1x glutam-
ine + 10% FCS (ThermoFisher Scientific) at 37 °C and
5% CO2 using the IncuCyte Live Cell Analysis System
(Sartorious, Goettingen, Germany). Cells were seeded
in 96 well plates (Corning), 15 × 104 cells per well 24 h
prior transfection to reach 80–90% confluence.
NTera2 cells were cultured with media only, Gankyrin
siRNA (100 μM; Qiagen) or siRNA control. Stau-
rosporine (300 nM; Sigma, Missouri, US) was used as a
positive control for apoptosis. Following 10 h incuba-
tion, media was replaced with the fluorogenic caspase
biosensor, NucView 488 (Biotium, Fremont, C. A,
U.S.A) diluted in DMEM +1x glutamine + 10% FCS, to
detect Cleaved Caspase-3 substrate in cells. Cells were
visualised and images were obtained at 72 h, using an
IncuCyte™ live cell imaging instrument and 20X Ob-
jective (Sartorius AG).
qPCR
RNA was extracted as per manufacturer’s instructions
using the Qiagen minikit (Qiagen, Hilden Germany),
and RNA quality/quantity was assessed using a Nano-
Drop (Thermofisher Scientific, Massachusetts, US).
cDNA synthesis was performed according to manu-
facturer’s instructions using the MAXIMA first strand
cDNA synthesis kit (ThermoFisher Scientific). qPCR
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was performed with SYBR green (Agilent techn-
ologies, Santa Clara, California, USA), according to
manufacturer’s instructions. RPS20 was used as
housekeeping gene [42] and expression levels of Gan-
kyrin, POU5F1, RB1, CDK4; TP53 and its downstream
genes P21, BAX, FAS, PAI, BAI and proliferation
genes Ki67, PCNA and TPX2 was investigated. Primer
details are described in Table 2.
Statistical analysis
Statistical analysis for all experiments was performed by
paired t-test using Graphpad prism 6.04 (GraphPad
Table 2 Primers sequences used for qPCR
Gene Forward Primer Reverse Primer
BAI1 CTAAGATGGCGAAGGTGGAG CTGTGGGATGAGACGGATGT
BAX GAGGATGATTGCCGCCGTGGACA GGTGGGGGAGGAGGCTTGAGG
FAS TGCACCCGGACCCAGAATAC GAAGACAAAGCCACCCCAAGTTAG
Gankyrin ATGAGGCTACAGCAATGCAC TACTTGCTCCTTGGGACACC
KI67 GAGGTGTGCAGAAAATCCAAA CTGTCCCTATGACTTCTGGTTGT
P21 CTGGCTCTTGATACCCCCCT TCAACACTGAGACGGGCTCC
PAI1 TGCTGGTGAATGCCCTCTACT CGGTCATTCCCAGGTTCTCTA
PCNA ACACGATTGGCCCTAAAGTCTTCCC GACCACTCTGCTACGCCTGCAACCG
POU5F1 CTTCTGCTTCAGGAGCTTGG GAAGGAGAAGCTGGAGCAAA
RPS20 AACAAGCCGCAACGTAAAATC ACGATCCCACGTCTTAGAACC
SRY ACAGTAAAGGCAACGTCCAG ATCTGCGGGAAGCAAACTGC
TP53 TCCACTACAACTACATGTGTAAC GTGAAATATTCTCCATCCAGTG
Fig. 1 Representative images for Gankyrin expression in human fetal testis and normal adult testis. Gankyrin (red), POU5F1 (green; gonocyte) and
MAGE-A4 (blue; prespermatogonia) expression in A), 11 week and B) 18 week old human fetal testis, counterstained with DAPI, yellow arrows –
gonocytes, white arrows – pre-spermatogonia, green arrows – differentiating gonocyte, orange arrows – Sertoli cells, Scalebars – 50 μm. C)
Representative image of Gankyrin expression in normal human adult testis immunostained for SOX9 (cyan; Sertoli cells), POU5F1 (green), MAGE-
A4 (blue; spermatogonia) and Gankyrin (red), Cyan arrow – spermatogonia. Scalebars – 50 μm, insets – no primary antibody controls. w-weeks.
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software INC., La Jolla, USA). For each experiment a
minimum of n = 3 (each with at least 3 technical repli-
cates) were used.
Results
Gankyrin is not expressed in gonocytes, but in a subset
of pre-spermatogonia in normal human fetal and adult
testis
In human fetal testis, triple immunofluorescent staining
with POU5F1, MAGE-A4 and Gankyrin was performed.
Nuclear expression of Gankyrin could not be detected
in gonocytes (POU5F1+/MAGE-A4−, yellow arrows,
Fig. a and b), but in a subset of pre-spermatogonia
(POU5F1−/MAGE-A4+, white arrows, Fig. 1b), nuclear
Gankyrin expression was found. Gankyrin was also
expressed in a subset of spermatogonia in adult testis
tissue with full spermatogenesis (blue arrows, Fig. 1c).
Abundant Sertoli cell expression of Gankyrin was
present in both normal fetal and adult testis (orange
arrows, Fig. 1).
Nuclear Gankyrin is expressed in a subset of GCNIS in
tissue from patients with pre-invasive or invasive TGCC
According to TGCC pathogenesis, there is a block of dif-
ferentiation of gonocytes, which then become GCNIS
and remain in the testis. After puberty these cells give
rise to tumours. The gonocytes are the precursor cells of
Fig. 2 Gankyrin expression pre-invasive germ cells. a) 1 year old - maturation delay; b) 2 year old – maturation delay; c) 7 year old pre-invasive
TGCC; d)17 year old pre-invasive TGCC; and e) 23 year old pre-invasive TGCC. Yellow arrows – GCNIS cells, orange arrows – Sertoli cells. This
experiment was performed along with human fetal testis samples, no primary antibody control is the same as on Fig. 1, Scalebars - 50 μm.
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GCNIS and therefore the expression profile of gonocytes
compared to GCNIS is important to examine potential
mechanism of malignant transformation. In human fetal
testis, gonocytes did not express nuclear Gankyrin
whereas in samples with maturation delay and in GCNIS
from both pre-pubertal and adult patients with pre-
invasive TGCC, nuclear Gankyrin was observed (yellow
arrows, Fig. 2). Similarly, nuclear Gankyrin expression
was observed in a subset of GCNIS cells from adult pa-
tients with invasive TGCC (yellow arrows, Fig. 3a-d). In
order to examine whether there was a difference in nu-
clear Gankyrin expression between MAGE-A4+ and
Fig. 3 Gankyrin expression in invasive TGCC. a-d Gankyrin (red), POU5F1 (green; GCNIS cells), and MAGE-A4 (blue; spermatogonia) expression in
GCNIS containing tubules from patients with invasive TGCC, yellow arrows – GCNIS cells, orange arrows – Sertoli cells. e and f Gankyrin (red),
POU5F1 (green; seminoma cells), and MAGE-A4 (blue) expression in seminoma cells (e) and a mixed TGCC (e), inset on D – no primary antibody
control. Scalebars - 50 μm.
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MAGE-A4− GCNIS cells in GCNIS from patients with
pre-invasive (n = 6) and invasive (n = 6) TGCC, we quanti-
fied Gankyrin expression in each sub-population. An
increased proportion of nuclear Gankyrin expression was
observed in POU5F1+/MAGE-A4− GCNIS compared to
POU5F1+/MAGE-A4+ GCNIS (Fig. S1). Gankyrin was also
detected in the cytoplasm of seminoma tumour cells and
the seminoma component of mixed non-seminoma, which
was determined by POU5F1 expression (Fig. 3e and f).
Knock-down of Gankyrin expression in NTera2 cells
results in a reduction in cell number without effects on
POU5F1 expression
To investigate the role of Gankyrin in malignant germ cells,
we used the embryonal carcinoma cell line (NTera2) to
perform Gankyrin knock-down in vitro using an siRNA ap-
proach. Gankyrin mRNA expression was significantly re-
duced (62%; p < 0.001) after 24 h, with a similar reduction
(50%; p < 0.01) at the protein level (Fig. 4a and b). The re-
duction in Gankyrin expression did not affect POU5F1 ex-
pression at either the mRNA or protein level (Fig. 4c-e).
Knock-down of Gankyrin expression resulted in a
significant reduction in the number of NTera2 cells
(32%; p < 0.01, Fig. 5a). To investigate this further, we
determined the expression of genes involved in cell
proliferation. Gankyrin knock-down did not affect the
expression of either PCNA or Ki67 (Fig. 5b and c);
however, cell cycle analysis demonstrated a small but
significant increase (4%; p < 0.05) in the proportion of
NTera2 cell in G0/G1 phase, with no significant effects
on other phases of the cell cycle (Fig. 5d-g).
To determine whether the effects on cell number in-
volved activation of apoptosis and/or cell cycle arrest,
we investigated the TP53 pathway (Fig. 6, A). Knock-
down of Gankyrin expression resulted in a significant
increase in TP53 expression (Fig. 6b) and several down-
stream genes including P21, BAX, FAS, and PAI-I (Fig.
6c-g). Functional image-based analysis using a cell-
permeable fluorescent caspase biosensor revealed
knockdown of Gankyrin resulted in activation of
Cleaved Caspase 3 (CC3) mediated apoptosis, whilst no
apoptotic cells were identified in controls (Fig. 6h).
Gankyrin knock-down enhances cisplatin mediated cell
death in NTera2 cell
TP53 has been shown to be important in mediating the
cytotoxic effect of cisplatin in TGCC [33, 43, 44], therefore
we investigated the role of Gankyrin in cisplatin sensitivity
in NTera2 cells. We confirmed the siRNA mediated
knock-down of Gankyrin expression in cisplatin exposed
NTera2 cells (Fig. 7a), and found that this resulted in a
significant reduction in the percentage of recovered live
cells compared to non-transfected untreated controls
(80%, p < 0.05) and non-transfected cisplatin treated con-
trols (50%, p < 0.05) (Fig. 7b). There was no effect of Gan-
kyrin knock-down on TP53 mRNA or protein expression
(Fig. 7c-e) however there was a significant increase in FAS
mRNA expression in cisplatin transfected cells (Fig. 7f).
Fig. 4 Effects of Gankyrin knock-down on Gankyrin and POU5F1 expression. Relative Gankyrin mRNA(a) and protein (b) expression in NTera2 cells
after Gankyrin knock-down. Relative POU5F1 mRNA (c) and protein (d) expression in NTera2 cells after Gankyrin knock-down. e Representative
Western blot for Gankyrin and POU5F1 expression in (V) vehicle and Gankyrin siRNA (T) transfected NTera2 cells. Tubulin was used as a loading
control. Data analysed by paired t-test ± SEM, ***p < 0.001, **p < 0.01. Each data point represents the mean of an individualexperiment, each with
3 replicates. Paired samples from an individual experiment are represented by the same colour.
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Discussion
The present study represents the first description of Gan-
kyrin expression in the normal human testis, testis with
maturation delay and in GCNIS from patients with pre-
invasive and invasive TGCC. In the human fetal testis, we
have shown that whilst nuclear expression of Gankyrin
was not detected in gonocytes (POU5F1+), nuclear Gan-
kyrin was observed in the nuclei of a sub-set of (pre)
spermatogonia (MAGE-A4+). This suggest Gankyrin
might be involved in normal germ cell differentiation.
GCNIS is believed to result from failure of differentiation
from gonocyte (POU5F1+) to (pre) spermatogonia
(POU5F1−) [4, 5]. Our observation that nuclear Gankyrin
is not expressed in gonocytes (POU5F1+/Gankyrin−) but
expressed in gonocytes from samples with maturation
delay and pre-GCNIS (POU5F1+/Gankyrin+) indicates
that Gankyrin expression is associated with the early stage
of TGCC development. Furthermore, within the GCNIS
cell populations, Gankyrin expression is present in a
higher proportion of POU5F1+/MAGE-A4− compared
with POU5F1+/MAGE-A4+cells, which may reflect an in-
creased oncogenic potential in the in the more prolifera-
tive POU5F1+/MAGE-A4− population [45].
Previous studies have demonstrated that Gankyrin
prevents POU5F1 degradation in HCC [23] and loss of
Gankyrin can reduce the oncogenic potential of tumour
cells through interaction with MAGE-A4 [26]. This,
combined with our previous finding of reduced onco-
genic potential in the POU5F1+/MAGE-A4+ population
of GCNIS cells compared with POU5F1+/MAGE-A4−
population [14] led us to hypothesize that Gankyrin ex-
pression might play a similar role in the pathogenesis of
Fig. 5 Effect of Gankyrin knock-down on cell number, cell proliferation and cell cycle of NTera2 cells. a Gankyrin knock-down effect on NTera2
cell number. Relative PCNA (b) and ki67 (c) expression after 24 h of Gankyrin siRNA transfection. Distribution of NTera2 cells in GO/G1 phase (d),
G2/M phase (e) or S phase (f). Data analysed by paired t-test, means ± SEM, ** p < 0.001, *p < 0.05. Each data point represents the mean of an
individual experiment, each with an 3 replicates. Paired samples from an individual experiment are represented by the same colour. (g)
Representative image of the flow cytometry plot obtained during cell cycle experiments.
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TGCC by preventing POU5F1 degradation and contrib-
uting to malignant progression.
Therefore, we investigated the effects of Gankyrin
knock-down in NTera2 cells, an established embry-
onal carcinoma cell line which is widely used in stud-
ies relating to TGCC [6, 46–48]. Transfection with
siRNA targeting Gankyrin resulted in a significant re-
duction (62%; p < 0.001) in Gankyrin expression. Gan-
kyrin knock-down did not affect POU5F1 mRNA or
protein expression in NTera2 cells demonstrating that
Gankyrin does not prevent POU5F1 degradation in
this cell line. Interestingly, we did find that Gankyrin
knock-down led to a significant reduction in cell
number suggesting a possible role for this protein in
the survival of malignant germ cells. Several studies
have demonstrated effect of Gankyrin on oncogenic
potential in hepatocellular carcinoma cells due to in-
creased cell proliferation and malignant transform-
ation of normal hepatocytes [20, 23, 24, 49, 50].
Given that knock-down of Gankyrin expression did
not affect the mRNA expression levels of proliferation
markers and induced only minor changes in the propor-
tion of cells in the different phases of cell cycle, we spec-
ulated that the reduction in cell number may be as a
result of an increase in apoptosis. A number of pro-
apoptotic genes are located downstream of TP53 and we
found that TP53 expression is upregulated following
knock-down of Gankyrin in NTera2 cells, which is in
Fig. 6 Gankyrin knock-down effect on TP53 and apoptosis. a TP53 pathway showing genes of interest in this study. Relative (b) TP53 (n = 4), (c)
P21 (n = 4), (d) BAX (n = 4), (e) FAS (n = 4), (f) BAI-1 (n = 6), (g) PAI-1 (n = 7) mRNA expression in NTera2 cells after Gankyrin knock-down. Data (b-g)
analysed by paired t-test, means ±SEM, *p < 0.05, **; p < 0.001. Each data point represents the mean of an individual experiment, each with 3
replicates. Paired samples from an individual experiment are represented by the same colour. H) Effects of Gankyrin knock-down on apoptosis in
NT2 cells using Nucview apoptosis (CC3) probe. Representative images of four separate experiments, each with 3 replicates.
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keeping with the results of a previous study [36]. Fur-
thermore, we have demonstrated that Gankyrin knock-
down results in an increased expression of apoptosis
genes BAX and FAS, both of which are downstream of
TP53. Down-regulation of Gankyrin also induces apop-
tosis in hepatocellular carcinoma cells with wild type
TP53 [35] whilst increased expression of Gankyrin in-
hibits apoptosis by causing degradation of TP53 protein
and reduced transcription of its downstream apoptotic
genes [35]. Furthermore, apoptotis was induced follow-
ing Gankyrin down-regulation, as indicated by Cleaved
Caspase 3 activity. Taken together these results suggest
that following Gankyrin knock-down in NTera2 cells the
reduction in cell number is likely to be mediated by an
increase in apoptosis mediated through the TP53 signal-
ling pathway leading to increased expression of the
apoptotic genes BAX and FAS.
Cisplatin, is the chemotherapeutic drug of choice for
treatment of TGCC, acting through the TP53 pathway
to induce DNA damage [33]. The expression of wildtype
TP53 in TGCC has been proposed to be a key determin-
ant for the effectiveness of cisplatin treatment [30]. This
might be related to the expression of a selected number
of embryonic microRNAs [51]. Previous studies have
reported that TP53 mutations did not occur in TGCC
[52], however recent studies have shown that 10 out of
148 patients with seminoma (7%) have a TP53 mutation
[53]. Although TP53 is abundantly present in its wild-
type form in TGCC, it has also been suggested that
TP53 is inactive in TGCC, given that its downstream
genes have been indicated as non-detectable [30]. Recent
studies have demonstrated that knockdown of TP53 in
NTera2 cells resulted in reduced cisplatin mediated
apoptosis [33, 34]. Therefore, given that we identified an
effect of Gankyrin knock-down on the TP53 and BAX/
FAS apoptosis pathway, we speculated that manipulation
of Gankyrin might modulate the effect of cisplatin in
TGCC. To test this, we combined Gankyrin knock-down
with cisplatin treatment in NTera2 cells. We showed
that Gankyrin knock-down enhances the reduction in
cell number caused by cisplatin treatment by 13% (p <
0.05), compared to cisplatin treatment alone. Taken to-
gether, these results suggest that Gankyrin plays a role
in cisplatin sensitivity and resistance.
Conclusion
In conclusion, we have demonstrated that Gankyrin is
expressed in the sub-populations of germ cells in the
Fig. 7 Effect of Gankyrin knock-down on cisplatin sensitivity in NTera2 cells. a Gankyrin mRNA expression after Gankyrin knock-down in cisplatin
(20 nM) exposed NTera2 cells. b Gankyrin knock-down and cisplatin treatment effect on the percentage of surviving cells Gankyrin knock-down
and cisplatin treatment effects on (c) TP53 mRNA and (d) protein expression. e Representative image for TP53 western blot in Vehicle (V) and
Gankyrin siRNA transfected (T) samples with and without cisplatin treatment and a no treatment control (NT). f Relative FAS mRNA expression
after Gankyrin knock-down and cisplatin treatment. CTL: control, CISP: cisplatin, VEH + CISP: vehicle and cisplatin, siRNA+CISP: Gankyrin
siRNA+cisplatin. Data analysed by paired t-test, means ±SEM, **p < 0.001, *p < 0.05. Each data point represents the mean of an individual
experiment, each with 3 replicates. Paired samples from an individual experiment are represented by the same colour.
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normal fetal and adult testis, as well as in pre-invasive
and invasive TGCC tissue from patients. We have also
demonstrated that repression of Gankyrin in NTera2
cells results in a reduction in total cell number and
enhances the cytotoxic effect of cisplatin in this TGCC
cell line. Together our results suggest that Gankyrin may
be a potential target for treatment of TGCC either as an
adjunct to cisplatin or in cisplatin resistant tumours.
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1186/s12885-019-6340-7.
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